Pomdoctor receives Nasdaq delisting notice after bid price stays below $1

Nasdaq notified Pomdoctor on October 6 that its ADSs failed the minimum bid price rule for 30 consecutive days. A 1-for-18 reverse split in June disqualifies the company from a cure period. Trading could be suspended October 15 unless the company appeals by October 13. Pomdoctor plans to request a hearing and present a compliance plan.